According to the World Health Organization (WHO), 8.2 million people died from cancer around the world in 2012, and cancer is now one of the leading causes of death. Lung cancer is the leading cancer type and caused 1.59 million deaths in 2012.
Small cell lung cancer is two types –
- Oat cancer
- Combiner small cell cancer
The major risk factors for small cell lung cancer are tobacco, alcohol, unhealthy food and physical inactivity. Some chronic infections also causes cancer. Having family history of lung cancer and being effected with the HIV also risk factors for small cell lung cancer
Symptoms of small cell lung cancer include coughing, blood in sputum, wheezing, chest pain, and shortness of breath. Current treatments are not cure the cancer in some patients with small cell lung cancer.
To treat small cell lung cancer following treatments are available:
- Radiation therapy
Doctors performed surgery to remove malignant tumor and lymph node.
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1244
Chemotherapy and radiation therapy given to the patient at a time to treat early stage of small cell lung cancer. Giving to treatments at a time to the patient is called concurrent chemo radiation.
Radiation therapy is given to the patient to shrink tumor cells as well as to relieve symptoms such as bleeding, cough, trouble swallowing and shortness of breath. Three-dimensional conformal radiation therapy (3D-CRT) and Intensity modulated radiation therapy (IMRT) are the two types of radiation methods used in the treatment.
Small Cell Lung Cancer (SCLC) Treatment Market: Drivers and Restraints
According to World Health Organization, cancer is the leading cause of death and it accounts 8.2 million deaths in 2012. Lung cancer is the leading cancer among the other cancers. For instance, 1.59 million people died with lung cancer around the world. Changing life style, smoking, increased alcohol consumption, unhealthy food, air pollution and no physical activity are indirectly driving the market. International healthcare organizations such as World Health Organization (WHO), National Cancer Institute, American Cancer Society also providing guidelines for cancer patients. Governments in the emerging economies are providing awareness among the people about the cancer. The above are driving factors for small cell lung cancer market.
Cost of the treatment and lack of awareness among the people for early detection of cancer are restrains for small cell lung cancer market
Small Cell Lung Cancer (SCLC) TreatmentMarket: Segmentation
Small Cell Lung Cancer (SCLC) Treatment market is segmented into following types
Based on Treatment
- Radiation Therapy
- Three-dimensional conformal radiation therapy (3D-CRT)
- Intensity modulated radiation therapy (IMRT)
- Platinum derivatives
- Topoisomerase Inhibitor
Based on End User
- Hospital Pharmacies
- Drug store
- Ambulatory Surgical Center
Small Cell Lung Cancer (SCLC) Treatment Market: Overview
Increasing awareness about cancer among common people and guidance from international organizations about the small cell lung cancer (SCLC) Treatment, the market is expected to have a healthy growth in the forecast period (2016-2026)
Visit For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1244
Small Cell Lung Cancer (SCLC) Treatment Market: Region- wise Outlook
Depending on geographic regions, the global Small Cell Lung Cancer (SCLC) Treatment market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific excluding Japan, Japan andMiddle East & Africa.
Small Cell Lung Cancer (SCLC) Treatment is high in North America because it is highly developed region, having good healthcare setup and people are having good awareness about health care. Asia Pacific is expected to grow at a remarkable CAGR. Europe also having good growth in this market.
Small Cell Lung Cancer (SCLC) Treatment Market: Key Players
Some of the key players in this market are Teva parenteral medicines inc., Bristol myers co, Novartis AG, Elekta AB, Siemens Healthcare GmbH, Bedford laboratories and App pharmaceuticals llc